Anaplastic oligoastrocytoma
MONDO:0016703An oligoastrocytoma characterized by the presence of increased cellularity, nuclear atypia, pleomorphism, and high mitotic activity.
Also known as: WHO grade III mixed glioma, aMOA, anaplastic mixed glioma, anaplastic oligoastrocytoma, AOAST
2832 clinical trials for this condition and its sub-types, 12 tagged with Anaplastic oligoastrocytoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Experimental combo targets Hard-to-Treat brain cancers
Disease control OngoingThis early-stage study tested the safety and best dose of vorinostat when given with the chemotherapy drug temozolomide in 83 adults with aggressive brain tumors called malignant gliomas. The goal was to see if adding vorinostat could make the tumor cells more sensitive to chemot…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Brain radiation showdown: proton vs. photon – which saves your mind?
Disease control OngoingThis study compares two radiation methods—proton beam and photon beam (IMRT)—in 120 people with slow-growing brain tumors (IDH-mutant gliomas). The goal is to see which better preserves memory and thinking over time. Participants are randomly assigned to one type of radiation and…
Phase 2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Chemo delivered straight to the brain: new hope for deadly tumors?
Disease control PausedThis study tests a technique that delivers two cancer drugs, bevacizumab and carboplatin, directly into the brain's arteries for people with recurrent glioblastoma or anaplastic astrocytoma. The goal is to see if this method is safe and can slow tumor growth better than standard …
Phase 1/2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Stem cells could help chemo target brain tumors
Disease control OngoingThis early-phase trial tests a new approach for people with aggressive brain tumors that have come back. Doctors place genetically modified neural stem cells directly into the tumor to make it more sensitive to the chemotherapy drug irinotecan. The study involves 18 participants …
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC